Event-free survival by disease assessment at 100 days and at 6, 9, 12, 18, and 24 months [clinicaltrials_resource:e540787ae5636582d8ec6ff9c37ecb2b]
The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Event-free survival by disease assessment at 100 days and at 6, 9, 12, 18, and 24 months [clinicaltrials_resource:e540787ae5636582d8ec6ff9c37ecb2b]
The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
Bio2RDF identifier
e540787ae5636582d8ec6ff9c37ecb2b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e540787ae5636582d8ec6ff9c37ecb2b
measure [clinicaltrials_vocabulary:measure]
Event-free survival by disease assessment
time frame [clinicaltrials_vocabulary:time-frame]
at 100 days and at 6, 9, 12, 18, and 24 months
description
The regimen varies according t ...... cord blood transplant (UCBT).
identifier
clinicaltrials_resource:e540787ae5636582d8ec6ff9c37ecb2b
title
Event-free survival by disease assessment at 100 days and at 6, 9, 12, 18, and 24 months
@en
type
label
Event-free survival by disease ...... 0787ae5636582d8ec6ff9c37ecb2b]
@en